Stifel analyst Paul Matteis reiterated a Buy rating and $118.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE